Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Top
Summary
All studies
Mortality
ICU
Hospitalization
Serious outcomes
Viral clearance
RCTs
RCT mortality
Peer-reviewed
All outcomes

Feedback
Home   COVID-19 treatment studies for Bebtelovimab  COVID-19 treatment studies for Bebtelovimab  C19 studies: Bebtelovimab  Bebtelovimab   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption

Outcomes in COVID-19 bebtelovimab studies

Outcomes in bebtelovimab studies. Efficacy is variant dependent. In Vitro research suggests a lack of efficacy for omicron BQ.1.1 [Planas]. Monoclonal antibody use with variants can be associated with prolonged viral loads, clinical deterioration, and immune escape [Choudhary].
0 0.5 1 1.5+ All studies 42% 5 12,949 Improvement, Studies, Patients Relative Risk Mortality 60% 4 12,478 ICU admission 59% 1 9,162 Hospitalization 35% 4 12,478 Viral clearance 36% 1 380 RCTs -151% 1 380 Peer-reviewed 46% 4 12,569 Early 42% 5 12,949 Bebtelovimab for COVID-19 c19early.org/bt Jun 2023 Favorsbebtelovimab Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Lilly (RCT) -151% 2.51 [0.10-61.1] death 1/252 0/128 Improvement, RR [CI] Treatment Control Dryden-Peterson 86% 0.14 [0.01-2.76] death 0/377 3/377 Kip 20% 0.80 [0.32-2.02] death/hosp. 6/157 15/314 Molina (PSM) 57% 0.43 [0.11-1.30] death 3/3,739 11/5,423 Sridhara (PSM) 86% 0.14 [0.01-2.76] death 0/1,091 3/1,091 Tau​2 = 0.00, I​2 = 0.0%, p = 0.13 Early treatment 42% 0.58 [0.29-1.16] 10/5,616 32/7,333 42% improvement All studies 42% 0.58 [0.29-1.16] 10/5,616 32/7,333 42% improvement 5 bebtelovimab COVID-19 studies c19early.org/bt Jun 2023 Tau​2 = 0.00, I​2 = 0.0%, p = 0.13 Effect extraction pre-specified(most serious outcome) Favors bebtelovimab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Lilly (RCT) -151% 2.51 [0.10-61.1] 1/252 0/128 Improvement, RR [CI] Treatment Control Dryden-Peterson 86% 0.14 [0.01-2.76] 0/377 3/377 Molina (PSM) 57% 0.43 [0.11-1.30] 3/3,739 11/5,423 Sridhara (PSM) 86% 0.14 [0.01-2.76] 0/1,091 3/1,091 Tau​2 = 0.00, I​2 = 0.0%, p = 0.078 Early treatment 60% 0.40 [0.14-1.11] 4/5,459 17/7,019 60% improvement All studies 60% 0.40 [0.14-1.11] 4/5,459 17/7,019 60% improvement 4 bebtelovimab COVID-19 mortality results c19early.org/bt Jun 2023 Tau​2 = 0.00, I​2 = 0.0%, p = 0.078 Favors bebtelovimab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Molina 59% 0.41 [0.17-1.03] 6/3,739 21/5,423 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.056 Early treatment 59% 0.41 [0.17-1.03] 6/3,739 21/5,423 59% improvement All studies 59% 0.41 [0.17-1.03] 6/3,739 21/5,423 59% improvement 1 bebtelovimab COVID-19 ICU result c19early.org/bt Jun 2023 Tau​2 = 0.00, I​2 = 0.0%, p = 0.056 Favors bebtelovimab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Lilly (RCT) -27% 1.27 [0.25-6.46] hosp. 5/252 2/128 Improvement, RR [CI] Treatment Control Dryden-Peterson 29% 0.71 [0.32-1.59] hosp. 10/377 14/377 Molina (PSM) 56% 0.44 [0.30-0.64] hosp. 38/3,739 107/5,423 Sridhara (PSM) 11% 0.89 [0.52-1.53] hosp. 24/1,091 27/1,091 Tau​2 = 0.09, I​2 = 45.6%, p = 0.061 Early treatment 35% 0.65 [0.42-1.02] 77/5,459 150/7,019 35% improvement All studies 35% 0.65 [0.42-1.02] 77/5,459 150/7,019 35% improvement 4 bebtelovimab COVID-19 hospitalization results c19early.org/bt Jun 2023 Tau​2 = 0.09, I​2 = 45.6%, p = 0.061 Favors bebtelovimab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Lilly (RCT) -151% 2.51 [0.10-61.1] death 1/252 0/128 Improvement, RR [CI] Treatment Control Dryden-Peterson 86% 0.14 [0.01-2.76] death 0/377 3/377 Kip 20% 0.80 [0.32-2.02] death/hosp. 6/157 15/314 Molina (PSM) 57% 0.43 [0.11-1.30] death 3/3,739 11/5,423 Sridhara (PSM) 86% 0.14 [0.01-2.76] death 0/1,091 3/1,091 Tau​2 = 0.00, I​2 = 0.0%, p = 0.13 Early treatment 42% 0.58 [0.29-1.16] 10/5,616 32/7,333 42% improvement All studies 42% 0.58 [0.29-1.16] 10/5,616 32/7,333 42% improvement 5 bebtelovimab COVID-19 serious outcomes c19early.org/bt Jun 2023 Tau​2 = 0.00, I​2 = 0.0%, p = 0.13 Effect extraction pre-specified(most serious outcome) Favors bebtelovimab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Lilly (RCT) 36% 0.64 [0.40-1.03] viral+ 33/252 26/128 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.066 Early treatment 36% 0.64 [0.40-1.03] 33/252 26/128 36% improvement All studies 36% 0.64 [0.40-1.03] 33/252 26/128 36% improvement 1 bebtelovimab COVID-19 viral clearance result c19early.org/bt Jun 2023 Tau​2 = 0.00, I​2 = 0.0%, p = 0.066 Favors bebtelovimab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Lilly (RCT) -151% 2.51 [0.10-61.1] death 1/252 0/128 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.58 Early treatment -151% 2.51 [0.10-61.1] 1/252 0/128 151% increased risk All studies -151% 2.51 [0.10-61.1] 1/252 0/128 151% increased risk 1 bebtelovimab COVID-19 Randomized Controlled Trials c19early.org/bt Jun 2023 Tau​2 = 0.00, I​2 = 0.0%, p = 0.58 Effect extraction pre-specified(most serious outcome) Favors bebtelovimab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Lilly (RCT) -151% 2.51 [0.10-61.1] 1/252 0/128 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.58 Early treatment -151% 2.51 [0.10-61.1] 1/252 0/128 151% increased risk All studies -151% 2.51 [0.10-61.1] 1/252 0/128 151% increased risk 1 bebtelovimab COVID-19 RCT mortality result c19early.org/bt Jun 2023 Tau​2 = 0.00, I​2 = 0.0%, p = 0.58 Favors bebtelovimab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Dryden-Peterson 86% 0.14 [0.01-2.76] death 0/377 3/377 Improvement, RR [CI] Treatment Control Kip 20% 0.80 [0.32-2.02] death/hosp. 6/157 15/314 Molina (PSM) 57% 0.43 [0.11-1.30] death 3/3,739 11/5,423 Sridhara (PSM) 86% 0.14 [0.01-2.76] death 0/1,091 3/1,091 Tau​2 = 0.00, I​2 = 0.0%, p = 0.091 Early treatment 46% 0.54 [0.27-1.10] 9/5,364 32/7,205 46% improvement All studies 46% 0.54 [0.27-1.10] 9/5,364 32/7,205 46% improvement 4 bebtelovimab COVID-19 peer reviewed studies c19early.org/bt Jun 2023 Tau​2 = 0.00, I​2 = 0.0%, p = 0.091 Effect extraction pre-specified(most serious outcome) Favors bebtelovimab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Lilly (RCT) -151% 2.51 [0.10-61.1] death 1/252 0/128 Improvement, RR [CI] Treatment Control Lilly (RCT) -201% 3.01 [0.12-73.2] death 1/127 0/128 Lilly (RCT) -27% 1.27 [0.25-6.46] hosp. 5/252 2/128 Lilly (RCT) -51% 1.51 [0.26-8.90] hosp. 3/127 2/128 Lilly (RCT) -2% 1.02 [0.15-7.16] hosp. 2/125 2/128 Lilly (RCT) 36% 0.64 [0.40-1.03] viral+ 33/252 26/128 Lilly (RCT) 38% 0.62 [0.35-1.10] viral+ 16/127 26/128 Lilly (RCT) 33% 0.67 [0.38-1.17] viral+ 17/125 26/128 Dryden-Peterson 86% 0.14 [0.01-2.76] death 0/377 3/377 Dryden-Peterson 43% 0.57 [0.28-1.19] death/hosp. 10/377 17/377 Dryden-Peterson 29% 0.71 [0.32-1.59] hosp. 10/377 14/377 Kip 20% 0.80 [0.32-2.02] death/hosp. 6/157 15/314 Molina (PSM) 57% 0.43 [0.11-1.30] death 3/3,739 11/5,423 Molina 59% 0.41 [0.17-1.03] ICU 6/3,739 21/5,423 Molina (PSM) 56% 0.44 [0.30-0.64] hosp. 38/3,739 107/5,423 Molina (PSM) 46% 0.54 [0.38-0.74] hosp. 48/3,739 116/5,423 Molina (PSM) -33% 1.33 [1.12-1.57] progression 260/3,739 275/5,423 Sridhara (PSM) 86% 0.14 [0.01-2.76] death 0/1,091 3/1,091 Sridhara (PSM) 25% 0.75 [0.43-1.31] death/hosp. 24/1,091 28/1,091 Sridhara (PSM) 11% 0.89 [0.52-1.53] hosp. 24/1,091 27/1,091 Bebtelovimab COVID-19 outcomes c19early.org/bt Jun 2023 Favors bebtelovimab Favors control
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit